Novel high-resolution and high-throughput technologies, such as tiling arrays and deep-transcriptome sequencing, have revealed that complex genomes give rise to non-coding RNAs (ncRNAs) 1,2 (FIG. 1) . ncRNAs are particularly abundant in the CNS [3] [4] [5] . It has been estimated that 40% of the genes for long ncRNAs (lncRNAs) are specifically expressed in brain tissue, and other types of ncRNAs, such as circular RNAs (circRNAs) and certain microRNAs (mi RNAs), have also been reported to be enriched in the CNS (and some specifically at synapses) [6] [7] [8] [9] [10] . Remarkably, research in the field of neurodegeneration has until now largely focused on a small percentage of the approximately 20,000 protein-coding genes. Protein-coding genes occupy less than 2% of the genome 11 , which inevitably raises the question as to whether we are overlooking an important part of the biology that underlies neurodegenerative disorders.
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The functional interrogation of the rapidly increasing number of annotated ncRNA sequences is a formidable challenge; therefore, critical experimental validation of the emerging evidence pertaining to the functions of these ncRNAs is required
. Nevertheless, recent years have seen a surge of studies underscoring the vital roles of ncRNAs in brain evolution, development, homeostasis, stress responses and plasticity [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Indeed, lossof-function studies have provided examples of the importance of ncRNA-mediated regulation in brain function [24] [25] [26] [27] [28] . Moreover, ncRNAs in the adult mouse brain often exhibit region-specific and stage-specific expression patterns 29, 30 and are dynamically regulated by neuronal activity 7, 8, [31] [32] [33] [34] [35] . Although most (but not all 36 ) ncRNA genes are expressed at relatively low levels, they may provide more information about cortical cell type identity than their protein-coding counterparts 13, 37 . Consistent with the observations mentioned above, ncRNAs have been implicated in brain ageing and in the pathophysiology of neuropsychiatric and neurodegenerative disorders 5, 12, 13, 38 . In this Review, we survey the emerging roles of ncRNAs in neurodegeneration and discuss the ways in which they challenge our understanding of neurodegenerative diseases and how they might lead to the development of novel diagnostic and therapeutic strategies.
ncRNAs in CNS homeostasis
During CNS development, ncRNAs affect stem cell maintenance, progenitor proliferation and cell fate choice 5, 13, 19, 25, 27, [39] [40] [41] . mi RNAs such as miR-124 and miR-132 have a marked positive regulatory impact on neurogenesis 42, 43 , whereas some lncRNAs, such as rhabdomyosarcoma 2 associated transcript (RMST) and Tcl1 upstream neuron-associated long intergenic ncRNA (TUNA), induce neuronal differentiation 17, 20 . Moreover, ncRNAs are implicated in neuronal fate commitment (for example, miR-124 (REF. 44 ), embryonic ventral forebrain 2 (Evf2) 18 , double-stranded neuron-restrictive silencer factor (dsNRSF) 45 and distal-less homeobox 1, antisense (Dlx1AS21)), glial specification (for example, miR-219 and miR-338 (REF. 46 ), Sox8 opposite transcript (Sox8OT) and nuclear enriched abundant transcript 1 (NEAT1) 21 , and NK2 homeobox 2 (Nkx2.2) 22 ) or both (for example, miR-9 (REFS 46, 47) and Gomafu 21, 35 ). A broad array of distinct ncRNA classes have been implicated in synaptic plasticity. These include small ncRNAs (mi RNAs 48 , endogenous small-interfering RNAs (endo-siRNAs), small nucleolar-derived RNAs 33 and PIWI-interacting RNAs (piRNAs)) 16 , long natural antisense transcripts (NATs) 49, 50 , enhancer ncRNAs (eRNAs) 32 circRNAs 7, 8 and other lncRNAs 51 (for example, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), NEAT1 (REF. 31 ) and Gomafu 35 ). Synaptically enriched ncRNAs, such as certain miRNA precursors, various mi RNAs (for example, miR-9, miR-132, miR-134 and miR-138) 52, 53 , BC1, BC200 (REF. 13 ) and most brain circRNAs 7, 8 , act as synaptic regulators in symphony with their protein-coding counterparts to regulate local protein expression 54 . A natural antisense transcript of BDNF (BDNF-AS) may negatively regulate synaptic plasticity by repressing the transcription of BDNF 50 , whereas another lncRNA, MALAT1, may be a positive regulator of synaptogenesis 15 . Epigenetic and transcriptional changes at the synapse contribute to memory consolidation and storage. A growing body of evidence demonstrates that ncRNA-mediated regulation is instrumental for memory formation 14, 55, 56 . Small ncRNAs, including mi RNAs 14, 56 , piRNAs 16, 55 and BC1 (REF. 56 ), are associated with cognitive and behavioural processes. Research on other ncRNA classes is still in its infancy. Importantly, knocking down an endogenous antisense ncRNA against Ub3a, a gene imprinted in Angelman syndrome, rescues some of the cognitive deficits that are observed in a genetic mouse model of this disorder 57 . Although the exact regulatory impact of several identified ncRNAs on memory and cognition remains elusive, the available evidence suggests that ncRNA networks are important for CNS homeostasis and that their dysregulation could have profound consequences for brain function.
ncRNA networks and neurotoxicity A number of distinct ncRNA classes are implicated in neurodegenerative disorders (Supplementary information S1 (table) ). Aberrations in the transcriptional networks in which these ncRNAs operate (BOX 2) may impinge on brain homeostasis in complex ways 58 (FIG. 2) . This is well illustrated by studies of the C9ORF72-associated hexanucleotide repeat expansion (GGGGCC), the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These repeat sequences are transcribed in both sense and antisense RNA and accumulate in nuclear RNA foci, the number of which correlates with pathologic severity in C9ORF72-related cases of ALS and FTD [59] [60] [61] . In addition, six dipeptide repeat proteins are translated from the C9ORF72 repeat locus (so-called repeat-associated non-ATG (RAN) translation) and co-aggregate in neuronal, ubiquitin-containing, intranuclear and cytoplasmic inclusions in the brain and spinal cord, possibly contributing to protein-mediated neurotoxicity mechanisms 62, 63 (FIG. 2) .
Spinocerebellar ataxia type 8 (SCA8) is similarly caused by multiple transcriptional products of SCA8. The sense strand gives rise to a trinucleotide repeat expansion transcript and to a polyglutamine expansion protein, which accumulates in intranuclear inclusions in cerebellar and brainstem neurons of transgenic mice and human autopsy tissue 64 . Moreover, a pathogenic repeat sequence is transcribed in the antisense direction. This sequence gives rise to a non-coding repeat RNA that overlaps, in terms of its genomic sequence, with the Kelch-like protein 1 (KLHL1) gene (the ncRNA gene is known as ataxin 8 (ATXN8) opposite strand (ATXN8OS) or KLHL1 antisense) 64, 65 . Transgenic mice overexpressing the human SCA8 expansion sequence display cerebellar deficits and progressive motor deficits that are similar to those observed in affected individuals . The accumulation of both sense and antisense expansion transcripts and of a polyglutamine expansion protein in these mice suggests that SCA8 pathology possibly involves both protein and RNA gain-of-function mechanisms . Non-protein coding genes may also have roles alongside protein-coding counterparts in fragile X syndrome (FXS), Huntington disease (HD) and Alzheimer disease (AD). The expansion of the microsatellite locus in the fragile X mental retardation 1 (FMR1) gene is associated with FXS (>200 CGG repeats, which is termed the full mutation) and the related condition, fragile X-associated tremor and ataxia syndrome (FXTAS) (55-200 CGG repeats, which is termed the premutation). This locus gives rise to the following four distinct transcripts with possible pathogenic relevance: the FMR1 repeat-containing mRNA; the FMR5 RNA, a sense ncRNA that is transcribed upstream of the FMR1 promoter; the FMR6 RNA, an antisense ncRNA Protein-coding genes account for approximately one-third of all annotated genes, whereas long and small non-coding RNA (ncRNA) genes together account for 40% of the gene set. Pseudogenes (genes derived from protein-coding loci that have lost their coding potential but may still exert regulatory functions) are not discussed here but are also present at high abundance. Numbers are derived from GENCODE, release 26 (http://www. gencodegenes.org/releases/current.html). lincRNA, long intergenic ncRNA; lncRNA, long ncRNA.
that overlaps the FMR1 3'-untranslated region (UTR); and, finally, FMR4, an antisense transcript from FMR1 that spans the repeat region 66,67 (FIG. 2) . These transcripts show different expression patterns in the brains of individuals carrying the premutation or the mutation.
This complex transcriptional fingerprint may contribute to the variability of the clinical phenotypes observed in FXTAS and FXS 66, 67 . Transcriptional silencing of FMR1 in patients with FXS leads to a deficit in its protein product, FMRP, an RNA-binding protein that regulates local protein translation in dendrites. Fmr1-knockout mice display synaptic alterations and cognitive impairment, suggesting a causal link between FMRP loss of function and FXS pathology 68 . However, FMR1 expansion-repeat RNA colocalizes with ubiquitin in intranuclear inclusions in post-mortem FXTAS brains 67 , and FMR4, which is also silenced in individuals with FXS, exerts antiapoptotic effects in human cell lines 69, 70 . These findings illustrate the complexity of the gain-of-function and loss-of-function mechanisms in brain disorders such as FXTAS and FXS.
In HD, a CAG repeat expansion in exon 1 of the gene huntingtin (HTT) is the primary cause of pathology. A small sense repeat transcript derived from the repeat-containing mRNA (small CAG-repeat RNA (sCAG)) is elevated in the brains of individuals with HD and is neurotoxic in vitro 71 , indicating that it might contribute to HD pathology. However, an antisense ncRNA overlapping the HTT repeat locus (HTT-AS) acts as an HTT repressor and is downregulated in the brain tissue of patients with HD 72 . As lowering mutated and wild-type HTT levels ameliorates pathology in HD mice 73 , HTT-AS should have a protective role in the disorder.
The evidence that crosstalk between coding and non-coding transcriptional networks has a role in AD is much less clear. Single-nucleotide poly morphisms (SNPs) in the vicinity of a locus giving rise to both antisense (antisense non-coding RNA in the INK4 locus (ANRIL; also known as CDKN2BAS)) and circular ANRIL (cANRIL) transcripts, which have been reported to be involved in epigenetic regulation, have been associated with AD pathology [74] [75] [76] [77] . These associations have not yet been . Nevertheless, a plethora of novel techniques for studying ncRNAs are now available. Direct visualization of long ncRNAs (lncRNAs) in single cells and at single-molecule resolution using RNA-fluorescence in situ hybridization (RNA-FISH) has yielded precise cellular and subcellular expression patterns for these molecules that may point towards distinct functional roles for ncRNAs 175, 176 . For instance, the particular localization of a ncRNA close to its own site of transcription inside the nucleus suggests that the ncRNA has a role in the transcriptional regulation of a proximal locus 175, 177 . In addition, high-resolution subcellular visualization of lncRNAs has shown that nuclear enriched abundant transcript 1 (NEAT1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and myocardial infarction associated transcript (MIAT) have roles in the formation of nuclear bodies (speckles and paraspeckles) 175, 176, 178 . Novel RNA-interactome approaches coupled to high-throughput sequencing allow in vivo identification of functional partners of ncRNAs. Chromatin isolation by RNA purification-sequencing (ChIRP), capture hybridization analysis of RNA targets (CHART) and RNA antisense purification (RAP) are employed for lncRNA-chromatin complex purification and identification of ncRNAs involved in topologically associating domains and nuclear organization 176, [179] [180] [181] . ChIRP-mass spectrometry (ChIRP-MS) and RAP-mass spectrometry (RAP-MS) are used for assessing RNA-protein interactions [182] [183] [184] [185] , and crosslinking, ligation and sequencing of hybrids (CLASH) is used for assessing RNA-RNA pairing 179 . In addition, several modified versions of each of these technologies, such as domain-specific ChIRP (dChIRP) 186 and identification of direct RNA interacting proteins (iDRiP)
187
, are emerging. Probing the secondary structure of ncRNAs using RNA-selective 2ʹ-hydroxylacylation and primer extension-sequencing (SHAPE-seq), parallel analysis of RNA structure (PARS) or fragmentation sequencing (FragSeq) 188 and mapping the tertiary structure of ncRNA-protein complexes by high-throughput technologies, such as crosslinking and immunoprecipitation-sequencing (CLIP-seq)
182
, RNA-massively parallel array (RNA-MaP) and RNA-mechanically induced trapping of molecular interactions (RNA-MITOMI), can provide key insights into ncRNA function 179, 189 . Assigning functional roles to ncRNAs requires loss-of-function approaches. Many were adapted from the mRNA world. Chemically modified antisense oligonucleotides, including antagomiRs or other synthetic molecules, such as microRNA (miRNA) sponges 190 and miRNA zippers 191 against mi RNAs and small-interfering RNAs (siRNAs), antagoNATs and antisense oligonucleotides (ASOs) against lncRNAs 174 , have been successfully used to knock down ncRNAs and unveil their functional roles in the cell. However, there are several limitations to performing ncRNA loss-of-function studies. siRNA approaches, for instance, turn out to be less effective when targeting nuclear transcripts, which is often the case for lncRNAs 173, 174 . Novel site-specific genome engineering based on transcription activator-like effector nucleases (TALENs) and the all-dominating CRISPR/Cas9 technologies are used to ablate whole ncRNA loci or their regulatory domains 173, 174, 192, 193 . Selective excision of the full or partial ncRNA sequence is not feasible when the ncRNA intersects other genes or when it is transcribed from bidirectional promoters, which would alter the transcription of neighbouring genes
174
. Moreover, the regulatory domains of lncRNA genes remain largely uncharacterized; therefore, domain-specific targeting is not always an option. Finally, in several cases, lncRNAs exert their function via the process of transcription per se; therefore, targeting the transcriptional product may not lead to a loss-of-function phenotype 173, 174 . Interestingly, a recent study demonstrated that only one-third of lncRNA loci are amenable to CRISPR applications without affecting additional genes 174 . Therefore, phenotypes are best confirmed using orthogonal approaches, such as siRNAs, ASOs and CRISPR.
Convergent transcription
Simultaneous transcription proceeding in the sense and antisense orientation from two closely positioned promoters, with the RNA polymerases heading towards each other.
confirmed in larger, classic genome-wide association studies (GWAS), but the observations may be of interest, as CDKN2B, which gives rise to these transcripts, encodes a protein involved in cell cycle regulation that accumulates in neurofibrillary tangles and amyloid plaques, two pathological features observed in the brains of patients with AD 78 . In addition, an antisense transcript from the glia-derived neurotrophic factor (GDNF) opposite strand gene (GDNFOS) gives rise -via alternative splicingto two ncRNAs and one protein and has been implicated in aberrant GDNF mRNA splicing in human AD brain tissue 79 . However, the functional consequences of these events for the physiological neurotrophic and neuroprotective functions of GDNF and the pathogenesis of AD remain unclear.
ncRNA mechanisms in neurodegeneration A growing list of studies illustrates the diversity of the roles of ncRNA in brain function and dysfunction (Supplementary information S1 (table)). Gaining a deeper understanding of ncRNA-mediated mechanisms of regulation will eventually facilitate their efficient therapeutic targeting. Here, we summarize six major mechanisms that likely contribute to the neurodegenerative process (FIG. 3; TABLE 1 ).
Epigenetic regulation. Chromatin immunoprecipitation (ChIP) assays demonstrate that ncRNAs with links to neurodegeneration associate with chromatin remodelling complexes and may therefore have roles in epigenetic regulation.
For example, ncRNA is associated with SCA7, in which polyglutamine repeat expansions in ATXN7 cause neurodegeneration 80 . Convergent transcription of SCA7 antisense non-coding transcript 1 (SCAANT1) suppresses Atxn7 transcription in the sense direction in mice 80 . SCAANT1 levels inversely correlate with ATXN7 mRNA levels in fibroblasts from patients with SCA7 and in transgenic mice carrying the repeat disease locus 80 . Hence, a mechanism of feedforward regulation has been proposed, wherein the repeat expansion in ATXN7 reduces SCAANT1 expression, which leads to de-repression of ATXN7 transcription and increased mutant ATXN7 levels 80 .
The lncRNAs BDNF-AS, taurine upregulated gene 1 (TUG1), maternally expressed 3 (MEG3), NEAT1 and TUNA, which may act as epigenetic regulators, are differentially expressed in brain tissue from humans with HD versus that from healthy individuals 17, [81] [82] [83] and might be involved in the pathological outcome by modifying the effects of mutant HTT. In particular, BDNF-AS, which shows activity-dependent expression, acts as a scaffold to recruit polycomb repressive complex 2 (PRC2) to the BDNF promoter, resulting in BDNF transcriptional repression in a human cell line 31, 50 . This regulatory effect may be of relevance in HD, in which BDNF is downregulated in the human brain 84 . Interestingly, BDNF overexpression rescues dopaminergic, synaptic, motor and cognitive deficits in a HD transgenic mouse model 82 , and BDNF-AS inhibition provides neuroprotection upon ischemic insult in retinal ganglion cells 85 . Importantly, the regulatory effects of all the differentially expressed lncRNAs mentioned above still await systematic experimental validation in HD models 17, 81 .
RNAi. Post-transcriptional repression of gene expression by mi RNAs and small-interfering RNAs (siRNAs) is collectively termed RNAi. Key molecular components shared between miRNA-mediated and siRNAmediated mechanisms are the RNase III endonuclease Dicer, which has a role in the generation of mi RNAs and siRNAs, and the Argonaute (AGO) protein family, which is a core component of the RNA-induced silencing ribonucleoprotein complex (RISC) that brings together the ncRNA and the mRNA target 86 . The binding of mi RNAs to their targets leads to either mRNA decay or translational inhibition. Global or individual manipulation of miRNA levels in the rodent brain can lead to neurodegenerative phenotypes 26, [87] [88] [89] . Indeed, genetic ablation of Dicer in adult mouse brain promotes hyperphosphorylation of tau and neuronal loss in the hippocampus 26 -both features of AD -and increasing the levels of the miRNA let-7 induces neuronal death in the mouse cortex 88 . miRNA expression profiles are perturbed across a wide spectrum of neurodegenerative disorders, including AD, Parkinson disease (PD), HD, ALS, FXS, FTD and SCA (Supplementary information S1 (table)). miRNA-mediated regulatory networks involve multiple targets; therefore, altered levels of one miRNA in the CNS might impact several layers of cellular homeostasis 90 . This is illustrated in experiments involving knockdown of miR-132, which is consistently and robustly
Box 2 | Non-coding transcriptome: from linear to three-dimensional networks
The genome does not follow simplistic human-created rules; hence, the dichotomy between 'coding' and 'non-coding' genes is an oversimplification, as we discuss in the main text 194 . In fact, protein-coding and non-coding transcribed domains from intergenic, intronic and intragenic regions and from both positive (sense) and negative (antisense) strands 5 illustrate the highly interlaced structure of the genome and its transcriptome 194 . Accordingly, RNA transcribed from a single DNA locus has multiple embedded functions and can give rise to several functional products 194 (FIG. 2) . For instance, many protein-coding genes can be transcribed in the antisense orientation (bidirectional transcription) and/or into circular transcripts 98, 195, 196 . Similarly, long non-coding RNAs (lncRNAs) often encompass small open-reading frames and are sometimes associated with ribosomes, suggesting that they might be involved in de novo protein synthesis 197, 198 , although this possibility remains controversial 13, 199, 200 . Nevertheless, the ability to encode small peptides has been experimentally validated for certain primary miRNA transcripts in plants 201 , microsatellite repeat expansions 202 , large intergenic ncRNAs (lincRNAs) 203 , natural antisense transcripts (NATs) 98 and the more recently identified circular RNAs (circRNAs) 196, 204, 205 . Continuous research has yielded an inventory of tens of thousands of ncRNAs 206 . The arbitrary designation of 'small' or 'long' (cutoff set at 200-400 nucleotides) has no functional foundation but, rather, reflects the technical aspects of biochemical RNA fractionation approaches. ncRNAs are expressed in a highly cell type-dependent, subcellular compartment-dependent, developmental stage-dependent and environmental context-dependent manner 41, 207 , and their flexible modular nature allows them to develop RNA-RNA, RNA-DNA and RNA-protein interactions
However, the question of what percentage of ncRNAs in the genome really is functional remains a matter of both semantic (when is a transcript defined as 'functional'?) and pragmatic (how much of the genome is implicated in evolutionary relevant trait specification, biological function or human-specific pathologies?) debate [208] [209] [210] [211] . Nature Reviews | Neuroscience 90, 91 . In AD transgenic mice, miR-132 downregulation in the hippocampus promotes both the accumulation of amyloid-β (a hallmark of AD) and tau hyperphosphorylation by upregulating inositol-trisphosphate 3-kinase B 92 . In addition, miR-132 inhibition in primary cortical and hippocampal neurons in vitro leads to the activation of the forkhead box protein O3 (FOXO3)-PTEN-P300 signalling pathway, which induces neuronal death 93 .
Other ncRNAs may also act via the RNAi pathway. The small neurotoxic repeat-containing transcript sCAG, which stems from HTT and is upregulated in the frontal cortex and caudate of individuals with HD and in brain tissue from HD transgenic mice, is loaded into the RISC to act as a gene silencer 71 . Interestingly, sCAG RNAs isolated from cells expressing human mutant HTT or from HD-affected human brain tissue markedly decreased the viability of human neuronal cells via an AGO2-dependent mechanism 71 . Antisense oligo nucleotides against sCAGs reversed this effect, supporting the idea that sCAGs have a role in mutant HTT-mediated neurotoxicity 71 . Conversely, the antisense ncRNA derived from the same HTT locus (HTT-AS) seems to also repress HTT expression via a Dicer-dependent regulatory mechanism. HTT-AS is downregulated in human HD brain tissue 72 . These observations suggest an interesting model in which the presence of the repeat expansion in the HTT-AS transcript represses its transcription, which may result in elevated mutant HTT levels in HD.
Alternative splicing. Shifting the splicing profiles of transcripts is another mechanism by which ncRNAs may affect pathology in neurodegenerative disorders. Sortilin related receptor 1 (SORL1) is a risk gene for late-onset AD that regulates the trafficking of amyloid-β precursor protein (APP) -from which amyloid-β is derivedand can be proteolytically processed by β-site APP cleaving enzyme 1 (BACE1; also known as β-secretase 1), which is involved in amyloid-β generation 94 . SORL1 levels are decreased in the brains of individuals with AD 94 , and Sorl1 ablation in mice induces amyloid-β formation by shifting APP from the retromer recycling pathway to the BACE1 proteolytic pathway 95 . An antisense transcript termed SORL1-AS (also known as 51A) shifts splicing so that transcripts for the alternative B and F isoforms of SORL1 are produced over the transcript for the canonical, long SORL1 isoform A, leading to downregulation of canonical SORL1. This shift in splicing is associated with increasing amyloid-β levels in cultured human neuronal cells 94 . Notably, SORL1-AS is upregulated in the human AD cortex, suggesting that it contributes to the SORL1 deficit and elevated amyloid-β production observed in the disease.
Another ncRNA that may be involved in AD, at least partly through influencing alternative splicing, is the lncRNA 17A. This ncRNA is upregulated in AD brain tissue 96 and may have a dual impact, as in neuroblastoma cells in vitro, it increases amyloid-β generation and induces alternative splicing of GABAB2, which encodes GABA B receptor subunit 2, abolishing signalling mediated by receptors containing this subunit 96 . In SCA8, ATXN8OS accumulates in RNA foci in the brain 97 . ATXN8OS promotes alternative splicing of the sodium-dependent and chloride-dependent GABA transporter 4 gene (Gabt4) and increased expression of the encoded protein in SCA8 transgenic mice 97 ; such changes are also observed in autopsy-obtained brain tissue from patients with SCA8 (REF. 97 ). Increased GABT4 levels have been linked to a reduction in GABA levels at synapses in cerebellar granular neurons 97 . In SCA8 transgenic mice, ATXN8OS was implicated in the loss of GABAergic inhibition in the cerebellar granular cell layer and the induction of a progressive : C9ORF72 loss of function, C9ORF72 repeat expansion-related RNA gain of function, and the generation of toxic dipeptide repeat proteins. Apart from a loss of function of FMRP, the protein encoded by the fragile X mental retardation 1 (FMR1) locus, toxic gain of RNA function has been also implicated in fragile X syndrome (FXS) 237 . The FMR1 locus generates three sense transcripts (one protein-coding and two non-coding transcripts, including FMR5) and two antisense non-coding transcripts (FMR4 and FMR6). A third example is the sense linear protein-coding transcript and the antisense circular ncRNA (ciRS-7, which acts as a sponge for the microRNA miR-7) that are both transcribed from the cerebellar degeneration-related antigen 1 (CDR1) locus. ciRS-7 downregulation (RNA loss of function) in the human Alzheimer disease (AD) brain has been associated with deficits in ubiquitin-mediated amyloid-β clearance in AD 101, 120 . The angled arrows indicate the direction of transcription of the sense and antisense transcripts. ncRNA transcripts can have a feedback regulatory effect on the protein-coding mRNAs. The combinatory transcriptional outcome of each locus affects the homeostatic balance in the CNS, and its disruption can impact neurodegenerative processes. Non-coding RNAs (ncRNAs) associated with neurodegenerative disorders may act at multiple functional levels to regulate a spectrum of molecular processes. ncRNAs can act as scaffolds to recruit transcriptional repressors or activators to chromatin-modifying complexes close to gene promoters and epigenetically silence (for example, HOTAIR, TUG1, MEG3, ANRIL, SCAANT1 and BDNF-AS) or induce (for example, NEAT1 and TUNA) gene expression in the nucleus. ncRNA regulation (for example, SORL1-AS, 17A and ATXN8OS) can induce preferential inclusion or exclusion of exons, thereby shifting mRNA splicing patterns towards certain alternatively spliced isoforms. ncRNAs in both the nucleus (for example, C9ORF72-derived ncRNA, MALAT1, NEAT1, FMR4 and LRP1-AS) and the cytoplasm (for example, lnc-SCA7 and ciRS-7) can bind proteins and other RNA molecules (for example, mRNAs, long ncRNAs (lncRNAs) and microRNAs (mi RNAs)) to titrate them away from their physiological places of function or guide them to different intracellular compartments. Binding of ncRNAs onto protein-coding transcripts may affect the stability of the latter and either protect them from degradation (mRNA stability) (for example, BACE1-AS, PINK1-AS and ciRS-7) or induce their decay by, for instance, employing the cellular components of the RNA-induced silencing ribonucleoprotein complex (RISC) (for example, mi RNAs, sCAG and HTT-AS). Translational induction or inhibition is another regulatory outcome of ncRNA-mRNA interactions in the cytoplasm. ANRIL, antisense non-coding RNA in the INK4 locus; ATXN8OS, ataxin 8 opposite strand; BACE-AS, β-site APP cleaving enzyme 1-antisense; BDNF-AS, brain-derived neurotrophic factor-antisense; ciRS-7, circular RNA sponge for miR-7; DRP, dipeptide repeat protein; FMR4, fragile X mental retardation 4; HOTAIR, HOX transcript antisense intergenic RNA; lnc-SCA7, long non-coding spinocerebellar ataxia type 7; HTT-AS, huntingtin-antisense; LRP1-AS, low-density lipoprotein receptor-related protein 1-antisense; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; NEAT1, nuclear enriched abundant transcript 1; PINK-AS, PTEN induced putative kinase 1-antisense; Pol II, RNA polymerase II; sCAG, small CAG-repeated RNA; SCANNT1, SCA7 antisense non-coding transcript 1; SORL1-AS, sortilin related receptor 1-antisense; TUG1, taurine upregulated gene 1; TUNA, Tcl1 upstream neuron-associated long intergenic ncRNA; UCHL1-AS, ubiquitin carboxyl-terminal hydrolase isozyme L1-antisense.
motor phenotype, linking a RNA gain-of-function mechanism directly to SCA8 pathology 97 . ATXN8OS might also regulate the splicing of its sense transcript, the mRNA for KLHL165, although the relevance of this effect to disease pathology is unknown.
Finally, the widespread alterations in FMR1 splicing profiles in the brain in FXS suggest that FMR6, a natural antisense FMR1 transcript that is downregulated in FXS brains, regulates the canonical splicing of FMR1 (in addition to having other effects) 66 . The functional validation of these observations may provide further insights into disease pathology. mRNA stability. Cytoplasmic RNA-RNA duplex formation between naturally occurring antisense and cognate sense transcripts can prevent endonucleolytic or exonucleolytic degradation of the sense mRNA or block access to proteins involved in RNA turnover, increasing its stability and translation 98 . For example, the ncRNA BACE1-antisense (BACE1-AS) binds BACE1 mRNA, leading to increased BACE1 levels in human cell lines and mouse brain tissues. As indicated above, BACE1 is one of the proteases that generate amyloid-β, and this enzyme has become a major drug target that is currently being studied in phase 3 clinical trials for AD. BACE1-AS levels are elevated in the brains of individuals with AD and in some transgenic mouse models of the disease 99 .
Moreover, BACE1-AS levels increase upon exposure to amyloid-β in vitro 99 , suggesting that a possibly deleterious positive feedback loop involving BACE1-AS and amyloid-β may be maintained during AD progression.
In contrast to BACE1-AS, circular RNA sponge for miR-7 (ciRS-7; also known as cerebellar degenerationrelated antigen 1-antisense (CDR1-AS)) is a strongly brain-enriched circular antisense ncRNA 100 that is downregulated in the cortex and hippocampus of patients with sporadic AD 101 . This ncRNA has mainly been studied for its role as a molecular decoy, which is discussed below. However, ciRS-7 also stabilizes -via an as yet unknown mechanism -its sense transcript, the mRNA for CDR1, which was first identified in patients with paraneoplastic cerebellar degeneration 100 . Of note, one preliminary report suggested that CDR1 levels might be increased in lymphocytes from patients with AD, but the importance of this observation for AD pathology in the human brain remains unclear 102 . Another example of a mRNA stability-related mechanism potentially linked to disease concerns an antisense transcript from the PTEN induced putative kinase 1 (PINK1) locus (PINK1-AS). Mutations in PINK1 are causally related to PD 103 , and PINK1-AS positively regulates the abundance of a specific splice variant of PINK1 (svPINK1) in neuroblastoma cells, possibly via RNA-RNA hybridization and transcript stabilization 104 . 
Seed sequence
Nucleotide sequences (2-7 nucleotides) in the 5ʹ-end of the microRNA (miRNA) sequence that are crucial for recognizing and binding to complementary sites on target mRNA 3'-untranslated regions (UTRs).
Finally, FMR6, which has already been discussed above, might stabilize FMR1 mRNA 66 . The findings relating to FMR6 and PINK-AS suggest that this ncRNAmediated regulation of disease-associated protein-coding transcripts might impact the activity of the related proteins and thereby modify disease progression, although this hypothesis requires further experimental validation in disease models.
Translational regulation. Certain ncRNAs have a direct impact on the translation of mRNA transcripts. BC200, a small neuron-specific ncRNA, is transported in ribonucleoprotein particles to the dendrites, where it forms part of a complex with multiple protein interactors (including FMRP) that regulates the translation of several mRNAs in the mouse brain 105 . Given that local translation in dendrites is involved in long-term synaptic plasticity and that BC200 levels markedly increase in the human AD brain, it is intriguing to hypothesize that BC200 might be implicated in the synaptic defects that are observed in AD 106 . Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1), a brain-enriched protein that is highly expressed in the substantia nigra, is involved in dopaminergic neuron differentiation and in the ubiquitinproteasome system. GWAS indicate that UCHL1 is a PD risk gene 107 . An antisense transcript for this gene (UCHL1-AS) targets Uchl1 mRNA to heavy polysomes for translation, resulting in increased UCHL1 levels 108 . In vitro PD models exhibit downregulation of both UCHL1-AS and Uchl1 mRNA, a finding suggestive of a possible link between UCHL1 and the proteasomal deficits that are observed in PD 109 .
Molecular decoys.
Owing to their highly versatile and modular nature, ncRNAs can act as molecular traps that titrate away an RNA (in this context, the ncRNAs are called competing endogenous RNAs (ceRNAs) 110 ) or a protein target 111 or transport them to specific cellular compartments. The relative abundance of the ncRNA decoy and its targets along with the number of target molecules that can be sequestered by one single ncRNA in a given cellular context are critical factors that determine the outcomes of such interactions 112, 113 . More specifically, the concentration of the ceRNA must approach that of the target miRNA to induce meaningful de-repression of the miRNA targets 113, 114 . The hexanucleotide repeat-containing C9ORF72 sense transcript, which is involved in FTD and ALS, co-accumulates with the antisense C9ORF72 ncRNA in nuclear and cytoplasmic RNA foci in human cultured cells and in patient brain tissue 60, 63 . Several RNA-binding proteins can be sequestered in these foci in brain tissue from humans with FTD or ALS and from mice with this expansion mutation, leading to altered RNA splicing or perturbed nucleocytoplasmic transport and possibly contributing to certain aspects of the pathology 63, 115 . The levels of the ncRNAs MALAT1 and NEAT1 are elevated in the brain of patients with frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP43) proteinopathy (FTLD-TDP), where they are the two most highly detected RNAs in TDP43-positive disease-associated inclusions 116 . In mammalian cells, MALAT1 and NEAT1 are implicated in recruiting splicing factors to subnuclear bodies known as speckles and paraspeckles, respectively 116, 117 . These observations clearly suggest that splicing aberrations contribute to disease, although the extent to which they influence the progression of pathology needs further assessment. This is also the case for the antiapoptotic transcript FMR4 (the antisense transcript of FMR1), which is highly expressed in individuals with FXTAS and silenced in individuals with FXS, and sequesters RNA-binding proteins into intranuclear inclusions in cultured human cells 67, 69 . The antisense ncRNA low-density lipoprotein receptor-related protein 1-antisense (LRP1-AS) can act as a molecular decoy for the ubiquitous chromatinassociated protein HMGB2, serving as a cell type-and locus-specific natural RNA ligand to fine tune HMGB2 activity in vitro 118 . This interaction obscures the binding of HMGB2 to its target, LRP1, resulting in reduced Lrp1 transcription. Interestingly, LRP1-AS is upregulated in the superior frontal gyrus in brain tissue from patients with AD, and its levels are inversely correlated with LRP1 levels 118 . Although cell biology studies suggest that LRP1 has a role in amyloid-β metabolism in the brain, the relevance of LRP1 regulation by LRP1-AS in AD pathology remains to be clarified.
The aforementioned circRNA ciRS-7 represents a unique example of multifunctionality. Notably, ciRS-7 is expressed at 200-fold higher levels than housekeeping proteins in human and mouse brains 100, 114 , suggesting that ciRS-7-mediated molecular trapping mechanisms in the CNS are stoichiometrically relevant. Apart from stabilizing CDR1 mRNA, as discussed above, human ciRS-7 harbours 74 seed sequence matches for miR-7 (which reflects a 10-fold higher miRNA-binding capacity than any other known transcript) and therefore acts as a miR-7 'sponge' in neuronal tissues 114, 119 . In brains from patients with AD, decreased ciRS-7 levels in the hippocampus and the cortex are associated with miR-7 upregulation and consequent repression of the miR-7 targets involved in ubiquitin-mediated clearance of amyloid-β 101 . In vitro, ciRS-7 promotes APP and BACE1 degradation by both the proteasomal and the lysosomal pathways, leading to decreased amyloid-β levels 120 . Hence, a complex link is emerging between ciRS-7 deficits and pathological amyloid-β aggregation in the AD brain. Moreover, as one of the targets of miR-7 is α-synuclein mRNA, which is encoded by SNCA, this regulatory network might have a role in PD as well 121 (α-synuclein is implicated in the pathophysiology of PD). Interestingly, transfection of a human cell line with miR-7 leads to a decrease in endogenous α-synuclein mRNA levels, a change that is counteracted by overexpression of ciRS-7 (REF. 114 ). ciRS-7 is degraded in a miR-671-dependent manner (possibly following direct ciRS-7-miR-671 base pairing) via AGO2-mediated cleavage in a human cell line 100 , suggesting that ciRS-7 acts to transport a cargo of miR-7 that becomes released by miR-671. Such spatio temporal control of miR-7 activity in the cell might go astray in neurodegeneration.
Finally, long noncoding-SCA7 (lnc-SCA7) acts as a miRNA decoy to regulate ATXN7 mRNA in a brain region-dependent manner 122 . More specifically, lnc-SCA7 competes with the ATXN7 transcript for binding to miR-124, thereby increasing ATXN7 levels in mouse and human neuroblastoma cells. Further experimental confirmation of these findings is required, as disruption of this tripartite regulation might play a role in SCA7 pathology, in which the levels of expansion repeat-containing ATXN7 are elevated 122 .
Genetic associations
Only 7% of the nearly 6,500 disease-predisposing or trait-predisposing SNPs that have been identified in more than 1,200 GWAS over the past decade are located in protein-coding regions, suggesting that most of these SNPs regulate gene expression rather than altering protein sequence or structure 123 . Interestingly, 75% of the SNPs that affect large intergenic ncRNA (lincRNA) expression do so in a tissue-dependent manner and without influencing the expression of neighbouring protein-coding genes 123 . Nevertheless, hard genetic proof that SNPs in ncRNA transcripts or ncRNA-interacting genomic loci have a causal role in neurodegeneration is lacking (Supplementary information S2 (table) ). For instance, a polymorphism in the 3ʹ-UTR of oxidized low-density lipoprotein receptor 1 (OLR1) mRNA may impair amyloid-β clearance from the brain across the blood-brain barrier (BBB) and was associated with cerebral amyloid angiopathy in a small cohort of patients with AD 124 . Moreover, a variation in the miR-433-binding site of FGF20 allows induction of both FGF20 and α-synuclein expression and is associated with an increased risk of PD 125 . FTLD-TDP can be caused by loss-of-function mutations in progranulin (GRN). A genetic variant in a binding site for miR-659 in the 3ʹ-UTR of GRN mRNA increases the binding of the miRNA to its target, resulting in stronger GRN repression. This variant has been reported by some studies to be a susceptibility factor for FTLD-TDP, AD and hippocampal sclerosis, although these findings require further confirmation by independent reports [126] [127] [128] [129] [130] . In another small-sized study, a similar polymorphism in one of the miR-146a-5p precursors was associated with a genetic predisposition for AD 131 . This polymorphism represses miR-146a-5p expression and consequently de-represses its target TLR2, which has been functionally implicated in amyloid-β-dependent inflammatory signalling cascades 131 . Recent findings suggest that SNPs in non-coding enhancer regions that are in close proximity to diseaseassociated loci (for example, SNPs in the SNCA locus, which is linked to PD risk) may affect gene expression in an organ-specific fashion, resulting in distinct disease phenotypes 132, 133 . Limited knowledge about the key functional elements in genes coding for ncRNAs and the rules of interaction among them as well as the overall lack of conservation of ncRNAs across different species obstruct the functional validation of genetic variations in these loci 134 . Indeed, developing an understanding of the molecular mechanisms governing ncRNA involvement in disease is dauntingly difficult, as SNPs in ncRNA genes could alter ncRNA expression or structure and/or their functional interactions with DNA, RNA or protein partners.
ncRNA diagnostics and therapeutics ncRNAs as biomarkers in neurodegenerative disorders. Alterations in miRNA levels in cerebrospinal fluid (CSF) and peripheral tissues in neurodegenerative disorders have been extensively documented [135] [136] [137] [138] [139] [140] [141] [142] [143] . Although it is clear that mi RNAs are markedly dysregulated in various neurodegenerative processes, most studies in this area have been monocentric and were relatively limited with regard to sample size. Between-study differences in the standardization of sample stratification, collection, processing, data normalization and analysis 136 explain why these reports have not yet yielded a consensus on which of the altered mi RNAs are relevant to disease. For instance, post-mortem delays in sample collection can be crucial, as miRNA levels in post-mortem CSF may not correlate well with those in brain tissue owing to compromised BBB integrity, which can result in the rapid entry of brain mi RNAs into the CSF 137 . The need for systematic and standardized approaches for profiling circulating mi RNAs in CSF and blood is evident.
Recent findings suggest that miR-206 levels (upregulated in the brain in AD) can be measured in olfactory mucosa in patients with mild cognitive impairment and that the expression of this miRNA correlates with cognitive deficit severity. These observations could prove exciting in the context of the early diagnosis of AD, as this approach may allow access to the molecular changes occurring in living cells 144 . It should be noted, however, that only 41 patients were investigated in this monocentric study, so further confirmation of these results is needed 144 . In patients with ALS or FTD, sense and antisense C9ORF72 RNA foci have been found in fibroblasts and lymphoblasts 61, 62 , and polyglutamine proteins have been detected in CSF 145 , suggesting that these RNA and protein species have potential as biomarkers. Again, the relatively low number of cases investigated (fewer than 10 cases per study) makes it imperative to repeat these studies in much larger patient cohorts to gain confidence in their diagnostic potential.
Although ncRNAs seem to be quite stable in body fluids (owing to their secondary structures) 1, 7 , further study is warranted to evaluate their potential as neurodegeneration biomarkers 146 . Efforts to set up large, multicentric and well-controlled studies to document ncRNA alterations in CSF and blood in a systematic way are necessary 147 .
Novel ncRNA-based therapies in neurodegeneration.
Targeting ncRNAs might offer effective approaches for the treatment of neurodegenerative disorders 12 . Successful targeting of lncRNAs will presumably be difficult because of their extensive secondary structures 146 ; however, improved oligonucleotide design has delivered multiple chemically modified analogues that may overcome such limitations 148 , and several of these tools have been successfully employed in experimental models of neurodegeneration 149 . Antisense oligonucleotides (ASOs) against the repeat-containing C9ORF72 transcripts and small molecules that inhibit RNA translation suppressed RNA foci formation in patient fibroblasts and in neurons derived from induced pluripotent stem cells from individuals with ALS. In C9ORF72 repeat-overexpressing mice, ASOs improved cognitive deficits 61, 145, [150] [151] [152] [153] . Furthermore, cleavage (siRNA) or inhibition (antagoNAT) antisense strategies against NATs potentially involved in AD and HD modulated the levels of both the NAT and its cognate sense mRNA in mouse and human cell lines and in the mouse brain 50, 99, 148 . Interestingly, inhibition of BACE1-AS lowered amyloid-β levels and improved adult neurogenesis in a mouse model of AD 154 , and an antagoNAT against BDNF-AS increased endogenous BDNF levels and promoted neuronal growth and survival in the wild-type murine brain 50 . Finally, emerging evidence suggests that blocking the generation of certain circRNAs may counteract TDP43-mediated cytotoxicity, and this was suggested as a potential therapeutic strategy for ALS 155 . A major advantage of single-stranded oligonucleotides, such as antagoNATs and ASOs, is that they can be administered systemically as 'naked' molecules (that is, without the requirement for any delivery vehicles) 148 .
Direct administration of oligonucleotides to the CNS has been achieved via intracerebroventricular or intrathecal infusion of CSF into rodents and non-human primates in tauopathy, HD, ALS and spinal muscular atrophy (SMA) animal models 73, 148, [156] [157] [158] [159] [160] . These approaches demonstrated that ASOs delivered in CSF efficiently enter the brain, where they engage their RNA targets. This in turn leads to up-or downregulation of the targeted transcripts or to shifts in splicing profiles and, eventually, to the amelioration of tissue toxicity and cognitive deficits.
Other emerging strategies for targeting the CNS include nanotechnology-based drug delivery systems. For instance, exosomes, which are nano-vesicles of endocytic origin, efficiently mediate the intercellular transfer of siRNAs, mi RNAs and miRNA antisense oligonucleotides in vitro [161] [162] [163] . In vivo, intravenous delivery of autologous dendritic cell-derived exosomes engineered for neuronal targeting and loaded with an siRNA against BACE1 resulted in marked brain-specific BACE1 mRNA and protein knockdown and a reduction in amyloid-β levels in the cortex of treated mice 164 . Their efficient and tissue-specific delivery along with the absence of overall immune responses underline the potential for using such RNA-based systemic therapeutic approaches in chronic neurodegenerative conditions.
Box 3 | ncRNAs as putative evolutionary signals of human brain development, ageing and neurodegeneration
The degree of organismal complexity correlates better with the proportion of non-coding RNAs (ncRNAs) in the genome than with the number of protein-coding genes (even when alternative splicing and post-translational modifications are considered as effectors of protein diversification) 25, [212] [213] [214] . This suggests that the evolution of biological complexity in eukaryotes largely stems from the increasing complexity of ncRNA biology [214] [215] [216] . ncRNA genes exhibit positive selection, accelerated evolution, species lineage-related expansion and specificity, preferential expression in the brain and selective associations with neural genes 36, [217] [218] [219] [220] . An appealing hypothesis to account for these phenomena is that ncRNAs may be mediators of certain behavioural and cognitive traits of higher organisms 207 , as opposed to CNS proteins, which are (apart from some limited examples of innovations in proteins) almost perfectly conserved across mammalian phyla 13, 54, [221] [222] [223] . Illustrating these principles, the rapidly evolving brain-specific and human-specific ncRNA human accelerated region 1F (HAR1F) is transcribed from a genomic region that has been subject to intense positive selection since human divergence from the great apes 224 and, along with several PIWI-interacting RNAs (piRNAs), large intergenic ncRNAs (lincRNAs), microRNAs (mi RNAs) and circular RNAs (circRNAs), is associated with human-specific brain development and function 195, 207, 219, 225, 226 . A genome-wide transcriptomic analysis in rat brain revealed that changes in ncRNA expression patterns are more prominent than changes in mRNA expression patterns during ageing 227 . ncRNAs with important functions in synaptic and other homeostatic processes, such as mi RNAs
228
, lncRNAs 229 , BC200 (REF. 106 ) and circRNAs, are differentially regulated in the ageing human brain. Moreover, the notion that the histopathological outcomes of brain ageing display profound differences across species raises the intriguing possibility that ncRNA-mediated regulation may be implicated in ageing-associated human neurological conditions 230 . The features of progressive mild atrophic brain alterations that mammalian laboratory models display are distinct from those of clinical neurodegenerative disorders associated with advanced ageing, such as cerebrovascular disease, Alzheimer disease (AD) and Parkinson disease (PD) 230 . Notably, no species except humans has shown evidence of major neuronal loss or massive cognitive decline that could compare to clinical grade AD 230 , an observation that cannot be attributed to primary structural differences in key protein players. The sequences of amyloid-β peptide (the main constituent of the amyloid plaques in AD) 231 , MAPT (the gene encoding tau, which precipitates into neurofibrillary tangles in tauopathies and AD) 232 and the genes encoding α-synuclein (which is implicated in PD) 233 and huntingtin (which is implicated in Huntington disease (HD)) 234 are almost identical in humans and other primates and, overall, are highly conserved among vertebrates. The existence of a human-specific natural antisense transcript (PTEN induced putative kinase 1 antisense (PINK1-AS)) that is implicated in PD
104
, the human-specific antisense ncRNA regulation of the ataxin-7 (ATXN7) locus in spinocerebellar ataxia type 7 (REF. 80 ) and the human-specific repression of HAR1F by restrictive element 1-silencing transcription factor (REST) along with its downregulation in the striatum of patients with HD 235 suggest that the evolutionary non-conserved ncRNAs might have an important contribution in human-specific neurodegenerative disorders. Clearly, more experimental evidence is required to support these observations; however, this will not be straightforward, and classic rodent systems may have to be replaced with more relevant 'humanized' models of neurodegeneration 236 .
These findings have not gone unnoticed by the pharmaceutical industry, and several companies are now focusing on ncRNAs (mi RNAs, NATs and lncRNAs) as potential treatments for various neurological disorders 146, 165 . Most of the practical attempts are still in the lead optimization phase, with only a few (against hepatitis C, lymphoma and fibrosis) having reached phase 1 and 2 clinical trials. Apart from the great hurdle of efficiently crossing the BBB (which is common to all CNS-targeting drugs), ncRNA-based therapeutics are also facing the issue of the differential targeting of the multiple transcriptional products generated by the same target locus and the associated complex biology. Nevertheless, clinical trials in patients with ALS or SMA that involve intra thecal delivery of ASOs against protein-coding transcripts have demonstrated the promise of therapeutically targeting RNA 166, 167 . Most notably, infants with type 1 SMA (the most severe form of the disease) that were enrolled in a recent phase 3 clinical trial showed markedly improved motor function following treatment with an ASO that interferes with the splicing of the transcript encoding SMN2, thereby boosting the levels of the SMN2 protein 167 .
Perspectives
Despite substantial progress in understanding ncRNA biology and its contribution to disease, we can safely state that we are in the early days of this field. The vast majority of the annotated ncRNAs have not been functionally investigated, and many questions remain unanswered regarding the impact of ncRNAs in the context of neurodegeneration. The only way forward is to perform more basic research to address the role of different ncRNAs in the brain, in specific brain areas, and in distinct cells. Larger, higher-powered and bettercontrolled ncRNA-profiling screens in human patients in CSF, blood and, indeed, brain are needed to map the changes in ncRNAs in disease with greater confidence 147 . In the meantime, novel insights, regarding mitochondrially encoded ncRNAs, ncRNA editing (epitranscriptomics) and epigenetic regulation of non-coding DNA, continue to emerge 40, 168, 169 . Systems biology and bioinformatic approaches are necessary to unravel the highly intricate networks in which ncRNAs operate 170, 171 . This will also require the implementation of novel experimental approaches, such as the currently rapidly evolving technologies used to screen the transcriptome at the single-cell level 37 or in different spatial contexts 172 . Looking ahead to the next decade, we anti cipate that valuable insights will be gained into how these fascinating molecules contribute to hitherto unknown aspects of pathogenic mechanisms and how they may be critical to understanding the human-specific aspects of neurological diseases
. Finally, we will hopefully witness improvements in the diagnosis and treatment of neurodegenerative disorders because of our developing understanding of ncRNAs.
